UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/626,585	07/25/2003	Poonsook Keelapang	ThaiBiotec004	9541	
Ms. Nuttina Ne	7590 05/15/200 tsuwan	EXAMINER			
113 Thailand So	cience Park, Paholyoth	CHEN, STACY BROWN			
Klong Luang, 1 THAILAND	2120		ART UNIT	PAPER NUMBER	
			1648		
			MAIL DATE	DELIVERY MODE	
			05/15/2009	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary		Applica	ation No.	Applicant(s)				
		10/626	,585	KEELAPANG ET AL.				
		Examir	ier	Art Unit				
		Stacy E	. Chen	1648				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply								
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).								
Status								
2a)⊠ This 3)⊡ Sine	sponsive to communication(s) files action is FINAL . ce this application is in condition sed in accordance with the pract	2b)☐ This action is for allowance exce	s non-final. pt for formal matters, p		merits is			
Disposition o	of Claims							
4a) 5)⊠ Cla 6)⊠ Cla 7)□ Cla	im(s) <u>1-9</u> is/are pending in the a Of the above claim(s) is/a im(s) <u>1-3</u> is/are allowed. im(s) <u>4-9</u> is/are rejected. im(s) is/are objected to. im(s) are subject to restri	are withdrawn from						
	•							
 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. 								
Priority unde	er 35 U.S.C. § 119							
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 								
2) Notice of [3] Information	References Cited (PTO-892) Draftsperson's Patent Drawing Review (n Disclosure Statement(s) (PTO/SB/08) s)/Mail Date	PTO-948)	4) Interview Summar Paper No(s)/Mail I 5) Notice of Informal 6) Other:	Date				

Application/Control Number: 10/626,585 Page 2

Art Unit: 1648

DETAILED ACTION

1. Applicant's amendment and remarks filed April 9, 2009 are acknowledged and entered.

Claims 1-6 and new claims 7-9 are pending and under examination.

Response to Amendment

- 2. The following objections are withdrawn:
 - The objection to the specification is withdrawn in view of Applicant's amendments to the specification.
 - The objections to claims 1-6 are withdrawn in view of Applicant's amendment.

Claim Rejections - 35 USC § 112

3. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

(*New Rejection*) Claims 5, 7 and 8 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. This is new matter rejection. The following embodiments do not appear to have been disclosed in the specification as originally filed:

 Claim 5 recites, "a wild type virus"; however the specification only provides support for a wild type dengue virus. Correction is required. Application/Control Number: 10/626,585 Page 3

Art Unit: 1648

 Claim 7 recites, "a mutant prM protein which substantially identical to the sequence depicted in SEQ ID NO: 1". The phrase does not appear in the specification as originally filed and there is no definition of what the phrase encompasses.

- Claim 8 recites, "is best at 29°C". The term "best" lacks support in the specification and claims as originally filed.
- 4. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 4, 6, 7 and 9 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The metes and bounds of the claims cannot be determined.

- Claim 4 recites, "the prototype dengue virus", which lacks antecedent basis in claim
 3.
- Claim 6 recites, "wherein the virus is exported out of the infected cells", which lacks
 antecedent basis in claim 3 because claim 3 does not recite anything about infected
 cells.
- Claim 7 is not clear with regard to the reference to a mutant prM protein which is "substantially identical to the sequence depicted in SEQ ID NO: 1". The phrase,
 "substantially identical" is relative and subject to individual interpretation. The level of identity required to meet "substantially identical" is not set forth in the specification.

Application/Control Number: 10/626,585 Page 4

Art Unit: 1648

Claim 9's recitation of "fusion by the mutant dengue virus is less efficient at 40°C" is unclear because the term "less efficient" is relative and lacks comparative basis. It is also not clear how the efficiency of cell fusion is measured such that one could determine that parameter.

Conclusion

5. Claims 1-3 are allowable.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Stacy B. Chen whose telephone number is 571-272-0896. The examiner can normally be reached on M-F (7:00-4:30). If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Nickol can be reached on 571-272-0835. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

/Stacy B Chen/ Primary Examiner, Art Unit 1648